--> this other competitor (second of 2) is years behind in the development process.
The correct other competive treatment is Javlor (per reference in the report referred to). Javlor is now being marketed but facing an uphill battle it seems. This is the most current info I could find on it. Likely not factored into the report as too close to publication date:
Pierre Fabre’s Javlor treatment for bladder cancer failed to win the backing of the U.K. National Institute for Health and Clinical Excellence in preliminary draft guidance on the treatment of advanced bladder cancer.
The study submitted by the privately held French company didn’t provide conclusive evidence of the drug’s clinical effectiveness, the agency, known as NICE, said today in an e- mailed statement. Javlor would cost more than 120,000 pounds ($193,000), “well above anything that NICE has previously accepted as cost-effective,” according to the statement. bloomberg.net
If interested in a more indepth overview of Javlor's status, see link below (from a different source):
https://www.pharmatimes.com/article/10-11-23/Bladder_cancer_drug_Javlor_too_costly_for_NHS_NICE_says.aspx
Sorry about that. rg